Cath Lab

The catheterization lab channel includes content related to interventional technologies for coronary and peripheral artery disease (PAD). Other cath lab transcatheter device technologies covered on this page included percutaneous treatment for stroke, venous interventions, heart valves, hypertension, heart failure and percutenous coronary interventions (PCI).

The stent struts of the Biotronik Orsiro stent.
News | Stents | December 21, 2020
New Stent Kink Resistance Testing Proposed in ASTM International Standard
December 21, 2020 – A proposed ASTM International standard will answer the need for a standardized test method that...
read more
A peripheral artery disease (PAD) patient CT scan showing blockages in the femoral arteries in the legs with collateral flow in the leg on the right.

A peripheral artery disease (PAD) patient CT scan showing blockages in the femoral arteries in the legs with collateral flow in the leg on the right.

News | Stents Bioresorbable | December 16, 2020
First-In-Human Use Reported for Bioresorbable Efemoral Vascular Scaffold System
December 16, 2020 — Efemoral Medical announced the first-in-human (FIH) use of the its Efemoral bioresorbable vascular...
read more
Videos | FFR Technologies | December 16, 2020
VIDEO: Example of the Medis QFR Angiography Image Derived FFR System
This is an example of the Medis Medical Imaging Quantitative Flow Ratio (QFR) system that offers a fractional flow...
read more
Videos | Robotic Systems | December 16, 2020
VIDEO: Corindus CorPath Robotic PCI System For The Cardiac Cath Lab
This is an example of the Siemens Corindus CorPath Cath lab robotic system being used for a percutaneous coronary...
read more
The Medis Quantitative Flow Ratio (QFR) is a novel, non-invasive, angiography-based physiologic FFR-like assessment of the presence and extent of coronary artery disease.

The Medis Quantitative Flow Ratio (QFR) is a novel, non-invasive, angiography-based physiologic FFR-like assessment of the presence and extent of coronary artery disease. 

News | FFR Technologies | December 16, 2020
Acist Medical Partners With Medis to Distribute Angiography Image Derived FFR Quantification System
December 16, 2020 – Acist Medical Systems Inc. announced a formal distribution partnership with Medis Medical Imaging...
read more
SoniVie, an Israeli company developing the Therapeutic Intra-Vascular Ultrasound (TIVUS) System to treat a variety of hypertensive disorders, announced that it has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). The  TIVUS System for renal artery denervation treats resistant hypertension, which is defined as blood pressure that remains above 140/90 mmHg despite use of three antihypertensive medications of different classes at the best tolerated doses.

SoniVie, an Israeli company developing the Therapeutic Intra-Vascular Ultrasound (TIVUS) System to treat a variety of hypertensive disorders, announced that it has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).

News | Renal Denervation | December 09, 2020
FDA Grants Breakthrough Device Designation for the TIVUS Renal Artery Denervation System
December 9, 2020 — SoniVie, an Israeli company developing the Therapeutic Intra-Vascular Ultrasound (TIVUS) System to...
read more
GE Healthcare is introducing a new, smaller and lighter weight robotic driven angiography system for image guided therapy, the Allia IGS 7 angiography system. #RSNA20 #RSNA2020

The GE Healthcare Allia IGS 7 angiography system.

News | Angiography | December 01, 2020
GE Introduces Robotic Angiography Gantry That Addresses Ergonomic Issues
December 3, 2020 — GE Healthcare is introducing a new version of its robotic driven angiography system for image guided...
read more
COVID-19 cardiology related content continues to be among the top performers on the DAIC website in November 2020. TAVR also topped headlines with Boston Scientific taking its Lotus valve off the market and a review of TAVR registry data showing it is now the dominant method of aortic valve replacement in the United States. #DAIC

COVID-19 cardiology related content continues to be among the top performers on the DAIC website in November 2020. TAVR also topped headlines with Boston Scientific taking its Lotus valve off the market and a review of TAVR registry data showing it is now the dominant method of aortic valve replacement in the United States.

Feature | Cardiovascular Business | December 01, 2020 | Dave Fornell, Editor
Most Popular Cardiology Technology Content in November 2020
December 1, 2020 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC)...
read more
A recent publication demonstrated procedural efficiency for MitraClip transcatheter mitral valve repair (TMVR) with use of the Baylis VersaCross RF Transseptal Solution, reporting guide delivery from femoral access in under 7.5 minutes.
News | Hemodynamic Monitoring Systems | December 01, 2020
Study Finds TMVR Procedural Efficiency Using the VersaCross RF Transseptal Solution
December 1, 2020 — A recent publication demonstrated procedural efficiency for MitraClip transcatheter mitral valve...
read more
One-year results off the PIONEER III study comparing the safety and efficacy of the Supreme HT drug-eluting stent (DES), to the Xience or Promus Durable Polymer DES showed it was equivalent in clinical performance to the market-leading DES. The results were presented at the 2020 American Heart Association (AHA) Scientific Session. #AHA2020 #AHA20 #AHA

One-year results off the PIONEER III study comparing the safety and efficacy of the Supreme HT drug-eluting stent (DES), to the Xience or Promus Durable Polymer DES showed it was equivalent in clinical performance to the market-leading DES. The results were presented at the 2020 American Heart Association (AHA) Scientific Session.

News | Stents | November 24, 2020
Biodegradable Drug Eluting Coronary Stent Noninferior to Xience or Promus Durable Polymer Stents
November 24, 2020 — One-year results off the PIONEER III study comparing the safety and efficacy of the Supreme HT (...
read more

The Edwards Lifesciences Sapien 3 TAVR valve. The annual volume of TAVR has increased each year and in 2019 TAVR volume (72,991) exceeded all forms of SAVR (57,626), coinciding with the U.S. Food and Drug Administration (FDA) approval of TAVR for low-risk patients. 

Feature | Heart Valve Technology | November 17, 2020
TAVR Is Now Dominant Form of Aortic Valve Replacement in the United States
November 17, 2020 — Since the approval of the first transcatheter aortic valve replacement (TAVR) device in 2011, more...
read more
oston Scientific Corp. announced today it is immediately retiring the entire Lotus Edge transcatheter aortic valve replacement (TAVR) system. It also initiated a global, voluntary recall of all unused inventory of the Lotus Edge due to complexities associated with the product delivery system. 
Feature | Heart Valve Technology | November 17, 2020 | Dave Fornell, Editor
Boston Scientific Pulls Lotus Edge TAVR Valve Off The Market
November 17, 2020 — Boston Scientific Corp. announced today it is immediately retiring the entire Lotus Edge...
read more
Women’s Heart Attack Research Program (HARP) shows combining OCT and cardiac MRI can detect the underlying cause of heart attack in women who did not have blocked arteries

The Women’s Heart Attack Research Program (HARP) study shows combining OCT and cardiac MRI can help detect the underlying cause of heart attacks in women who did not have blocked arteries.

News | Cardiac Imaging | November 17, 2020
OCT Combined with MRI Can Identify Cause of Unexplained Heart Attacks in Women
November 17, 2020 — Diagnostic imaging techniques were able to find the underlying cause of heart attack in many women...
read more
Omega-3 fish oil supplements did not help patients after a heart attack in AHA 2020 study. #AHA #AHA20 #AHA2020. Getty Images

Omega-3 fish oil supplements did not help patients after a heart attack. Getty Images

News | Pharmaceuticals | November 17, 2020
Omega-3s Do Not Reduce Cardiac Events in Recent Heart Attack Survivors
November 17, 2020 — A daily dose of omega-3 fatty acids did not reduce the risk of cardiac events, including secondary...
read more
Among high-risk, chronic, coronary patients who undergo angioplasty, there were no additional benefits from ticagrelor compared to the current standard of care clopidogrel. #AHA #AHA20 #AHA2020
News | Cath Lab | November 16, 2020
Ticagrelor Not Superior to Clopidogrel in Reducing Heart Attacks During PCI
November 16, 2020 — The use of the more potent antiplatelet medication ticagrelor (Brilinta) was not superior to...
read more
© Copyright Wainscot Media. All Rights Reserved.